American Society of Hirudotherapy

Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management

Review published in Drug safety (1997)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentSalivary PharmacologyWarkentin · Drug safety, 1997

Abstract

Heparin-induced thrombocytopenia (HIT) is an immunoglobulin-mediated adverse drug reaction associated with a high risk of thrombotic complications. The pathogenic antibody, usually immunoglobulin (Ig) G (HIT-IgG), recognises a multimolecular complex of heparin and platelet factor 4, resulting in platelet activation via platelet Fc receptors. In addition to in vivo platelet activation, it is now recognised that there is a concomitant activation of coagulation, as shown by marked elevations in thrombin-antithrombin complex levels. It is possible that this increased thrombin generation predisposes HIT patients to a newly recognised complication: warfarin-induced venous limb gangrene. This syndrome is characterised clinically by necrosis complicating deep venous thrombosis in the absence of large-vessel arterial occlusion, and appears to result from acquired protein C deficiency during warfarin therapy for deep vein thrombosis and HIT. The recommended treatment for HIT is an agent that reduces thrombin generation, either indirectly via factor Xa inhibition [e.g. danaparoid sodium (a mixture of anticoagulant glycosaminoglycans)] or directly using a specific thrombin inhibitor (e.g. recombinant hirudin; argatroban). HIT is potentially preventable: there is a lower frequency of HIT, associated thrombosis and HIT-IgG seroconversion in patients treated with low-molecular-weight heparins, compared with unfractionated heparin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnimalsAnticoagulantsHeparinHumansThrombocytopenia

Summary

This review of heparin-induced thrombocytopenia describes its pathogenesis via heparin-platelet factor 4 antibodies, complications such as warfarin-induced venous limb gangrene, and recommended treatments including recombinant hirudin and argatroban to reduce thrombin generation.

Why This Matters for Hirudotherapy

This review covers pathogenesis, frequency, avoidance, and management of heparin-induced thrombocytopenia (HIT), describing it as an IgG-mediated adverse drug reaction with platelet activation and increased thrombin generation, and discussing warfarin-induced venous limb gangrene as a possible complication. For treatment, the abstract lists agents that reduce thrombin generation, including recombinant hirudin as one example of a direct thrombin inhibitor, alongside argatroban and indirect option danaparoid sodium. This mention of recombinant hirudin is the only point of contact with leech therapy. The abstract does not state that hirudin is leech-derived, discuss hirudotherapy or live leech therapy, or single out recombinant hirudin as the recommended treatment.

Citation

Reference (Vancouver style)

Warkentin TE. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Saf. 1997;17(5):325-341. doi:10.2165/00002018-199717050-00005. PMID: 9391776

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.